☆ 3.9 Article

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

CLINICAL OPHTHALMOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Pharmacology & Pharmacy

The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases

Lorenzo Ferro Desideri et al.

Summary: Simultaneously targeting the VEGF and Ang/Tie pathways may be more beneficial than monotherapy in patients with exudative retinal diseases. Among the investigational drugs targeting the Ang/Tie pathway, faricimab has shown promising results in phase II/III trials and in the near future may represent a viable treatment option for the management of exudative macular diseases.

EXPERT OPINION ON THERAPEUTIC TARGETS (2022)

添加到收藏夹

Article Medicine, General & Internal

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Jeffrey S. Heier et al.

Summary: The primary results of two Phase 3 trials show that faricimab can effectively improve visual acuity for patients with nAMD at intervals of up to 16 weeks, with comparable safety profile to aflibercept. This suggests that faricimab has the potential to reduce treatment burden by extending the time between injections while maintaining efficacy.

LANCET (2022)

添加到收藏夹

Article Ophthalmology

Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration

Adam H. Ross et al.

EYE (2020)

添加到收藏夹

Article Ophthalmology

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration The AVENUE Phase 2 Randomized Clinical Trial

Jayashree Sahni et al.

JAMA OPHTHALMOLOGY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease

Rehan M. Hussain et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)

添加到收藏夹

Article Ophthalmology

nPredictability of Recalcitrance in Neovascular Age-Related Macular Degeneration With Indocyanine Green Angiography

Ryan B. Rush et al.

ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY (2015)

添加到收藏夹

Article Ophthalmology

TREAT-AND-EXTEND BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION The Importance of Baseline Characteristics

Ryan B. Rush et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2014)

添加到收藏夹

Editorial Material Ophthalmology

Two Year SAVE Outcomes: 2.0 mg Ranibizumab for Recalcitrant Neovascular AMD

Charles C. Wykoff et al.

OPHTHALMOLOGY (2013)

添加到收藏夹

Article Ophthalmology

ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

David M. Brown et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)

添加到收藏夹

Article Ophthalmology

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration

Daniel F. Martin et al.

OPHTHALMOLOGY (2012)

添加到收藏夹

Article Ophthalmology

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

Jeffrey S. Heier et al.

OPHTHALMOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

Ranibizumab for neovascular age-related macular degeneration

Philip J. Rosenfeld et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.